Related Experiment Video
Updated: Sep 27, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Enhanced Metabolic Risks in Patients with Obesity and Nutritional Deficiencies in the U.S.: A TriNetX Study
Elvia Y Osorio1, Zbigniew Gugala2, Peter C Melby1,3,4,5
1Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA.
Background/Objectives:
Nutrient deficiencies associated with progression from obesity to metabolic dysfunction are poorly characterized. Using electronic health records (TriNetX Research Network), we evaluated the association between key nutritional deficiencies and metabolic outcomes among patients with obesity.
Methods:
Deficiencies assessed included protein-energy malnutrition, deficiencies in vitamin D, calcium, magnesium, and vitamin B12, and prior underweight status. Outcomes included severe obesity, prediabetes, type 2 diabetes, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD), and metabolic dysfunction-associated steatohepatitis (MASH). After matching propensity scores, cohorts with the double burden of malnutrition (DBM) were compared with a reference cohort of patients with obesity but no history of nutritional deficiencies.
Results:
The most prevalent types of DBM were vitamin D deficiency (10.6%), protein deficiency (8.9%) and calcium deficiency (7.5%). Incidence rates of obesity and all types of DBM increased from 2023 to 2025. Although middle-aged White and Black/African American patients represented the largest demographic groups, adults aged >70 years exhibited higher incidence rates of protein, calcium, magnesium, and B12 deficiencies. Vitamin D deficiency (median hazard ratio [HR] 3.09; IQR 2.32-5.66), vitamin B12 deficiency (median HR 2.49; IQR 2.16-6.08), and prior underweight (median HR 2.23; IQR 1.76-3.98) were associated with the highest burden of metabolic diseases.
Conclusions:
These findings underscore the interplay between nutritional deficiencies and metabolic disease risk in obesity and support targeted interventions for populations affected by DBM, especially older adults, and in the context of racial and socioeconomic disparities.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Drug Dosing: Obese Patients
Obesity
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Bioavailability Study Design: Healthy Subjects Versus Patients